Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Pharma Equity Group

0.09 DKK

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Compare
0.00 %
-11.00 %
-4.71 %
-4.91 %
-23.93 %
-36.20 %
-80.65 %
-80.96 %
-99.66 %

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more
Market cap
109.25M DKK
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 2025-09-10

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16/4
2026

General meeting '26

14/8
2026

Interim report Q2'26

All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release3/25/2026, 3:10 PM

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group
Regulatory press release3/25/2026, 11:50 AM

Pharma Equity Group A/S - Annual Report 2025

Pharma Equity Group
Press release3/18/2026, 12:24 PM

UPDATE OF THE FINANCIAL CALENDAR FOR 2026

Pharma Equity Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/11/2026, 7:00 AM

Analyst Group: Pharma Equity Group deltar på Analyst Groups och Direkt Studios kapitalmarknadsdag onsdag den 11 mars

Pharma Equity Group
Regulatory press release2/26/2026, 3:24 PM

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025

Pharma Equity Group
Press release2/3/2026, 7:00 AM

2026 Financial Calendar

Pharma Equity Group
Press release12/30/2025, 1:31 PM

Analyst Group: Analyst Group Comment on Pharma Equity Group’s Strategic Update and Adjustment of Expectations

Pharma Equity Group
Regulatory press release12/29/2025, 3:31 PM

Pharma Equity Group – Strategic update and adjustment of expectations

Pharma Equity Group
Press release12/11/2025, 9:20 AM

Analyst Group: Analyst Group Comment on Pharma Equity Group’s Letter of Intent to Acquire MedTech Company Otiom A/S

Pharma Equity Group
Regulatory press release12/10/2025, 11:17 AM

Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S

Pharma Equity Group
Regulatory press release12/3/2025, 7:19 AM

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group
Regulatory press release12/1/2025, 12:10 PM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Regulatory press release11/26/2025, 3:40 PM

Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority

Pharma Equity Group
Regulatory press release10/1/2025, 7:24 AM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point
Research9/10/2025, 6:31 AM by
Philip Coombes

Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point

PEG maintained its guidance with its H1 2025 results, for DKK 11m in partner-driven revenue. The recent approval to initiate its RNX- 011 Phase IIb clinical trial strengthens PEG’s partner negotiation position.

Pharma Equity Group
Regulatory press release9/2/2025, 8:03 AM

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group
Press release9/1/2025, 12:32 PM

Analyst Group: Analyst Group Comment on Pharma Equity Group’s regulatory approval to initiate Phase II clinical trial for RNX-011

Pharma Equity Group
Regulatory press release9/1/2025, 11:06 AM

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group
Press release8/28/2025, 8:11 AM

Analyst Group: Analyst Group Interview Pharma Equity Group's CEO Christian Tange

Pharma Equity Group
Press release8/21/2025, 12:28 PM

Analyst Group: Equity Research Report on Pharma Equity Group - Successful Execution Hinges on Financing

Pharma Equity Group
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.